Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nucleoside analogs: similarities and differences

J P Sommadossi1

  • 1Department of Pharmacology, University of Alabama, Birmingham 35294.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy.

AIDS (London, England)·2004
Same author

4'-C-methyl-beta-D-ribofuranosyl purine and pyrimidine nucleosides revisited.

Nucleosides, nucleotides & nucleic acids·2003
Same author

Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus.

Antimicrobial agents and chemotherapy·2002
Same author

Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Antiviral beta-L-nucleosides specific for hepatitis B virus infection.

Antiviral chemistry & chemotherapy·2001
Same author

Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil).

The Journal of antimicrobial chemotherapy·2001
Same journal

Understanding the Clone-Censor-Weight Method in Observational Studies of Antibiotic Duration.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T Cells.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Protection Against Recurrent Typhoid Fever Conferred by a Prior Episode: Evidence from a Large Cohort Study in Dhaka, Bangladesh.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Pre-treatment Gut Microbiome Diversity and Function Linked to Cytotoxic and Natural Killer Cell Immune Responses after N-803 Treatment in People with HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Reconsidering ambiguous language in infectious disease consult recommendations.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Nucleoside analogs are key anti-HIV drugs requiring intracellular activation. Their varying toxicity and resistance highlight the importance of host cell enzymes and viral reverse transcriptase mutations.

Area of Science:

  • Virology
  • Pharmacology
  • Molecular Biology

Background:

  • Human immunodeficiency virus (HIV) replication involves targets for antiviral chemotherapy.
  • HIV reverse transcriptase is a primary target for anti-HIV drug development.
  • Nucleoside analogs are a class of anti-HIV drugs requiring intracellular metabolic activation.

Purpose of the Study:

  • To explore nucleoside analogs as anti-HIV drugs targeting viral reverse transcriptase.
  • To understand the role of host cell enzymes in nucleoside analog activation.
  • To investigate the mechanisms of toxicity and resistance associated with nucleoside analogs.

Main Methods:

  • Review of nucleoside analog mechanisms of action against HIV.
  • Analysis of intracellular enzyme-dependent activation of nucleoside analogs.

Related Experiment Videos

  • Examination of pharmacokinetic profiles and toxicity of 2',3'-dideoxynucleosides.
  • Investigation of HIV reverse transcriptase mutations leading to drug resistance.

    • Main Results:

    • Nucleoside analogs require intracellular metabolism to active 5'-triphosphates.
    • Enzyme activity for activation varies by host species, cell type, and cell cycle.
    • 2',3'-dideoxynucleosides exhibit favorable intracellular pharmacokinetic profiles.
    • Multifactorial toxicity mechanisms contribute to diverse toxicity profiles among analogs.
    • HIV strains resistant to zidovudine have emerged due to reverse transcriptase mutations.

    Conclusions:

    • Nucleoside analogs are critical in HIV therapy, but their efficacy depends on host cell factors.
    • Understanding drug metabolism and resistance mechanisms is essential for effective HIV treatment.
    • Individual nucleoside analogs possess unique properties influencing their therapeutic potential and toxicity.